New Initiative Aims To Address Gap In Access To Injectable Contraceptives In Africa, South Asia

“For many women, injectable contraceptives have tremendous advantages: one shot of the popular Depo-Provera protects for three months. It is safe and effective, with almost no risk of unintended pregnancy,” Sara Tifft, a senior program officer for reproductive health at PATH, writes in USAID’s “IMPACTblog.” “Depo-Provera is very popular in sub-Saharan Africa and has great potential to reach millions more women,” she writes, adding, “A new initiative announced at the London Summit on Family Planning in 2012 aims to address this gap in access.” She notes, “USAID, the Bill & Melinda Gates Foundation, DFID, UNFPA, and PATH will bring up to 12 million doses of a new form of Depo-Provera, called Sayana Press, to women in sub-Saharan Africa and South Asia” (5/31).

The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.

KFF Headquarters: 185 Berry St., Suite 2000, San Francisco, CA 94107 | Phone 650-854-9400
Washington Offices and Barbara Jordan Conference Center: 1330 G Street, NW, Washington, DC 20005 | Phone 202-347-5270 | Email Alerts: | |

The independent source for health policy research, polling, and news, KFF is a nonprofit organization based in San Francisco, California.